Perpetua Medical AB (PERP-B) Fair Value & Analysis
Healthcare · Market cap 31.4M SEK
Fair value as of: Jul 18, 2026
From 15 valuation models · updated 4 days ago
Share price +8.2% over the past month.
Price vs Fair Value (12 months)
12‑month range kr 3.03 – kr 5.56 · fair‑value band kr 3.71 – kr 6.09 · the kr 3.56 price screens below the kr 4.87 fair value. As of Jul 18, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Perpetua Medical AB (PERP-B) currently trades at kr 3.56, while our model-based Fair Value estimate is kr 4.87, implying the stock looks roughly 36.8% undervalued today. We read business quality at 30/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium), always confirm before acting.
Over the trailing twelve months, Perpetua Medical AB generated revenue of 14.6M SEK at a net margin of 16.8%. Revenue grew 23.8% year over year. It earns a return on equity of 5.8%. The balance sheet holds a net cash position of 4.2M SEK. Fundamentals as of Jul 18, 2026
Our scenario range runs from kr 3.71 (bear case) to kr 6.09 (bull case); at kr 3.56, the current price sits below that range. The share trades about 41% below its 52-week high and 17% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -22% fair-value upside, at 37%, PERP-B screens cheaper than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 18, 2026. TTM = trailing twelve months.
About the company
Perpetua Medical AB (publ) provides products and solutions for use of injectable drugs in Sweden. The company provides DrugLog, a solution for reducing medication errors in pharmacy; WasteLog, a device that analysis waste and returns of injectable controlled substances; and PrepLog, a DrugLog based technology platform that integrated prescription software or medication management system for the test of drug preparations. The company formerly known as Pharmacolog i Uppsala AB (publ) and changed its name to Perpetua Medical AB (publ) in April 2024. Perpetua Medical AB (publ) was incorporated in 2007 and is headquartered in Uppsala, Sweden. Perpetua Medical AB (publ) operates as a subsidiary of Nolsterby Invest AB.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Perpetua Medical AB reported revenue of kr 14.6M in FY2025 versus kr 8.8M in FY2021, a compound +13.4%/yr. Reported net income was kr 2.5M in FY2025.
Is PERP-B fairly valued? → Check now
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jul 18, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | $86.97 | $69.36 | -20% |
| Stryker Corporation SYK | $305.66 | $187.83 | -39% |
| Medtronic plc MDTC34 | R$210.63 | R$24.08 | -89% |
| Boston Scientific Corporation B1SX34 | R$248.75 | R$221.81 | -11% |
| Edwards Lifesciences Corporation EWL | €75.46 | €37.29 | -51% |
| Siemens Healthineers AG SEMHF | $39.95 | $44.36 | +11% |
| DexCom, Inc DXCM | $74.77 | $53.93 | -28% |
| GE HealthCare Technologies Inc GEHC | $60.64 | $65.03 | +7% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥143.50 | ¥111.50 | -22% |
| Koninklijke Philips N.V PHG | $26.98 | $10.24 | -62% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Perpetua Medical AB (PERP-B) undervalued?
What is the fair value of PERP-B?
What is the quality score of PERP-B?
What is the revenue of Perpetua Medical AB (PERP-B)?
What is the net profit margin of PERP-B?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Unlock the full Perpetua Medical AB analysis, and try Pro free
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.